Therapeutic Asset Ratings

3,774 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Ucar T-Cell Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis	The Children's Hospital of Zhejiang University School of Medicine	P1	CCC (50)
Ucar T-Cell IgA Glomerulonephritis	The Children's Hospital of Zhejiang University School of Medicine	P1	CCC (50)
Ucar T-Cell Systemic Lupus Erythematosus	The Children's Hospital of Zhejiang University School of Medicine	P1	CCC (50)
Allogeneic Cd8+ Leukemia-Associated Antigens Specific T Cells Nexi-001 Acute Myeloid Leukemia	City of Hope Medical Center	P1/2	CCC (50)
Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells Cerebral Infarction	Sclnow Biotechnology Co., Ltd.	P1/2	CCC (50)
Ari-0001 Mantle Cell Lymphoma	GUSTAVO SALGUERO	P1/2	CCC (50)
cd7.car/28zeta car t cells T-Cell Acute Lymphoblastic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (50)
cd7-specific car gene-engineered t cells T-Cell Acute Lymphoblastic Leukemia	Shenzhen Geno-Immune Medical Institute	P1/2	CCC (50)
Chimeric Antigen Receptor Modified T Cells Infusion Classical Hodgkin Lymphoma	New York Medical College	P1/2	CCC (50)
Dc-Cik Pancreatic Ductal Adenocarcinoma	University of Malaya	P2/3	CCC (50)
Egfr/B7H3 Car-T Glioblastoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	P1/2	CCC (50)
hem101 B-Cell Non-Hodgkin Lymphoma	National Research Center for Hematology, Russia	P1/2	CCC (50)
Mb-Cart20.1 B-Cell Non-Hodgkin Lymphoma	Miltenyi Biomedicine GmbH	P1/2	CCC (50)
Neuroncell-Ex Ischemic Stroke	Cytopeutics Sdn. Bhd.	P2/3	CCC (50)
scg101 Hepatocellular Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CCC (50)
Sscart-19 B-Cell Non-Hodgkin Lymphoma	Shanghai Tongji Hospital, Tongji University School of Medicine	P1/2	CCC (50)
Targeting Cd276 Car T Cells Neuroblastoma	Shenzhen Geno-Immune Medical Institute	P1/2	CCC (50)
TIL Brain Neoplasm	Essen Biotech	P1/2	CCC (50)
TIL Breast Carcinoma	Essen Biotech	P1/2	CCC (50)
Platelets Traumatic Brain Injury	Jason Sperry	P2	CCC (49)
Treg Cells Acute Myeloid Leukemia	Antonio Pierini	P2	CCC (49)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Colorectal Cancer	BOE Technology Group Co., Ltd.	P1/2	CCC (49)
Anti-Cd33 Car T-Cells Acute Myeloid Leukemia	Zhejiang University	P1/2	CCC (49)
cll1 car t-cells Acute Myeloid Leukemia	Tongji Hospital	P1/2	CCC (49)
gc012f Plasma Cell Myeloma	Gracell Biotechnologies (Shanghai) Co., Ltd.	P1/2	CCC (49)

Showing 551 to 575 of 3,774 assets

PreviousPage 23 of 151Next